Newly presented data indicate that treatment with SYMBICORT® (budesonide/formoterol fumarate dihydrate) inhalation aerosol results in significantly greater improvements in lung function and a lower risk of asthma worsening episodes compared to budesonide and/or formoterol used alone. In addition, data also showed that SYMBICORT was generally well tolerated, with an adverse event profile similar to that of its individual components. These study results, involving patients with mild to moderate persistent asthma, were presented at the American College of Allergy, Asthma & Immunology’s (ACAAI) annual scientific sessions in early November.
SYMBICORT is a newly approved, twice-daily, inhaled combination therapy containing budesonide (BUD), a corticosteroid, and formoterol (FM), a rapid and long-acting β2-agonist. It is indicated for the long-term maintenance treatment of asthma in patients ages 12 and older. SYMBICORT is for patients not adequately controlled on other asthma-controller medications or whose disease severity clearly warrants initiation of treatment with two maintenance therapies.
“Asthma is a serious, sometimes life-threatening, disease that can greatly impact lung health and function when not properly managed,” said Jonathan Corren, MD, clinical associate professor of Medicine and Pediatrics Division of Clinical Immunology and Allergy, University of California, Los Angeles. “These data demonstrate that in patients with persistent asthma symptoms, SYMBICORT provides advantages over its individual components in improving lung function and asthma control, as well as preventing asthma attacks.”